1 – 10 of 40
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Genome-wide CRISPR/Cas9 screen identifies regulators of BCMA expression on multiple myeloma cells
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Decreased neutrophil function in newly diagnosed multiple myeloma patients is restored with lenalidomide therapy
2024) In European Journal of Haematology(
- Contribution to journal › Article
-
Mark
Large differencies in age-specific survival in multiple myeloma in the nordic countries
(
- Contribution to journal › Debate/Note/Editorial
- 2022
-
Mark
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group
(
- Contribution to journal › Article
- 2021
-
Mark
Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden
(
- Contribution to journal › Article
-
Mark
Germline variants at SOHLH2 influence multiple myeloma risk
(
- Contribution to journal › Article
-
Mark
Bone Marrow Neutrophils of Multiple Myeloma Patients Exhibit Myeloid-Derived Suppressor Cell Activity
(
- Contribution to journal › Article
- 2020
-
Mark
Outcome and characteristics of non-measurable myeloma : A cohort study with population-based data from the Swedish Myeloma Registry
(
- Contribution to journal › Article
-
Mark
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
(
- Contribution to journal › Article
-
Mark
Search for multiple myeloma risk factors using Mendelian randomization
(
- Contribution to journal › Article